Program
dexibuprofen
Also written as “Dexibuprofen”, “S-Ibuprofen Gel 5%” and “S-Ibuprofen”.
Its studies are mostly in Contusions · Acute Pain · Osteoarthritis, Hip, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Aponia Laboratories | 21 open or running | phase 3since Oct 25, 2026 | Feb 20, 2019 | Jun 2027phase 3 · NCT07930559 |
| Apsen Farmaceutica | 20 open or running | phase 1since Nov 1, 2016 | Nov 1, 2016 | none ahead |
| Gebro Pharma | 20 open or running | phase 4since Feb 9, 2010 | Mar 1, 2007 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 1, 2007First study: phase 1 study in Drug InteractionsNew to Gebro PharmaGebro Pharma · NCT00442585 · 72 enrolled · Austria
- Feb 9, 2010Phase 4 study in Osteoarthritis, HipGebro Pharma · NCT01066676 · 482 enrolled · Austria
- Nov 1, 2016Apsen Farmaceutica's first studies: 2 phase 1 studies in Healthy VolunteersNew to Apsen FarmaceuticaApsen Farmaceutica · NCT02956525, NCT02956512
- Feb 20, 2019Aponia Laboratories's first study: phase 2 study in Acute PainNew to Aponia LaboratoriesAponia Laboratories · NCT03852459 · 251 enrolled · United States
- Oct 25, 2026Phase 3 study in ContusionsPhase 3 reachedAponia Laboratories · NCT07930559 · 240 planned · United States, Germany
Ahead
- Jun 2027Primary completion: phase 3 study in ContusionsAponia Laboratories · NCT07930559
TargetBeta
“Cyclooxygenase inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Acetaminophenrule | Johnson & Johnson | phase 4 | 136 |
| Ibuprofenrule | Pfizer | phase 4 | 113 |
| Aspirinrule | Bayer | phase 4 | 84 |
| dexketoprofenrule | Menarini Group | phase 4 | 8 |
| Sulfasalazinerule | Bristol-Myers Squibb | phase 4 | 7 |
| Benzydaminerule | Angelini Pharma | phase 4 | 4 |
| Dipyronerule | Hypera Pharma | phase 4 | 4 |
| Piroxicamrule | Taisho Pharmaceutical | phase 4 | 4 |
| Flurbiprofenrule | GlaxoSmithKline | phase 3 | 12 |
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07930559Contusions · United States, Germany | 3 | Recruiting | Aponia Laboratories | Jun 2027 | 240 |
| NCT03852459Acute Pain · United States | 2 | Completed | Aponia Laboratories | Apr 4, 2019 | 251 |
| NCT02956525Healthy Volunteers · Brazil | 1 | Completed | Apsen Farmaceutica | Jul 1, 2018 | 52 |
| NCT02956512Healthy Volunteers · Brazil | 1 | Completed | Apsen Farmaceutica | Jul 12, 2019 | 52 |
| NCT01066676Osteoarthritis, Hip · Austria | 4 | Completed | Gebro Pharma | Jun 2012 | 482 |
| NCT00442585Drug Interactions · Austria | 1 | Completed | Gebro Pharma | 72 |
How it is read
Names in the registry
- “Dexibuprofen”, 3 entries
- “S-Ibuprofen Gel 5%”, 1 entry
- “S-Ibuprofen”, 1 entry
- “S(+)-ibuprofen”, 1 entry
Conditions, from the studies’ own filings
- Contusions, 1 study
- Acute Pain, 1 study
- Osteoarthritis, Hip, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.